NGNE Neurogene Inc

Price (delayed)

$30.93

Market cap

$618.95M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.04

Enterprise value

$514.47M

?
Relative Growth: Rel. Growth: 2
Relative Strength: Rel. Strength: 88
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 5

Neoleukin is a biopharmaceutical company that has historically created next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin developed sophisticated computational methods to design ...

Highlights
NGNE's debt is down by 24% year-on-year and by 9% since the previous quarter
NGNE's quick ratio is down by 41% YoY and by 19% from the previous quarter
Neurogene's net income has decreased by 32% YoY and by 13% QoQ

Key stats

What are the main financial stats of NGNE

NGNE stock price

How has the Neurogene stock price performed over time
Intraday
-7.95%
1 week
-10.79%
1 month
-19.93%
1 year
83.56%
YTD
50.15%
QTD
-1.65%

Financial performance

How have Neurogene's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$121.35M
Net income
-$111.11M
Gross margin
N/A
Net margin
N/A
Neurogene's net income has decreased by 32% YoY and by 13% QoQ
NGNE's operating income is down by 27% year-on-year and by 10% since the previous quarter

Price vs fundamentals

How does NGNE's price correlate with its fundamentals

Growth

What is Neurogene's growth rate over time

Valuation

What is Neurogene stock price valuation
P/E
N/A
P/B
2.25
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NGNE's EPS is down by 17% YoY and by 11% QoQ
The stock's price to book (P/B) is 88% more than its 5-year quarterly average of 1.3 and 75% more than its last 4 quarters average of 1.4
NGNE's equity is down by 21% YoY and by 9% QoQ

Efficiency

How efficient is Neurogene business performance
The company's return on invested capital has shrunk by 58% YoY and by 33% QoQ
The ROE has contracted by 35% YoY and by 19% from the previous quarter
NGNE's return on assets is down by 35% year-on-year and by 18% since the previous quarter

Dividends

What is NGNE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NGNE.

Financial health

How did Neurogene financials performed over time
NGNE's quick ratio is down by 41% YoY and by 19% from the previous quarter
Neurogene's current ratio has decreased by 41% YoY and by 19% QoQ
NGNE's debt is 96% smaller than its equity
NGNE's debt is down by 24% year-on-year and by 9% since the previous quarter
NGNE's equity is down by 21% YoY and by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.